According to the Zhitong Finance App, Daren Tang (600329.SH) disclosed the 2023 annual report. The company achieved revenue of 8.222 billion yuan in 2023, a year-on-year decrease of 0.33%; net profit to mother of 987 million yuan, an increase of 14.49%; deducted non-net profit of 952 million yuan, an increase of 23.8%; and basic earnings per share of 1.28 yuan. The company plans to distribute a cash dividend of 12.8 yuan (tax included) for every 10 shares to all shareholders
In 2023, the company will firmly implement the eight major action frameworks of “focus on the market, effective innovation, organizational governance, co-creation and sharing, drive both industry and finance, control capital and loss, digital empowerment, and cultural brand”. The company's industrial revenue was 4.930 billion yuan, maintaining double-digit year-on-year growth and reaching a new high.
The system promotes the “three core and nine wings” strategy, and has a track record of continuing to cultivate the main products. Sales of over 100 million varieties reached 10. Among them, sales of quick-acting heart saving pills surpassed 2 billion yuan for the first time, while clean-throat drops, Angong beef yellow pills, Jingwanhong Ointment, and anti-lung anti-inflammatory pills entered the 200 million yuan category.